Morepen Laboratories has launched Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.
Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality. The product range includes Empagliflozin (Empamore 10mg/25mg) and Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg).
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1731.20 |
Dr. Reddys Lab | 1162.35 |
Cipla | 1483.00 |
Lupin | 2019.20 |
Zydus Lifesciences | 891.05 |
View more.. |